Form 4: Lemaitre Vascular Insider Reports Routine Stock Changes
Insider Transaction Report
Lemaitre Vascular President and Director David B. Roberts reported routine transactions involving common stock and dividend equivalent rights.
Summary
- David B. Roberts, President and Director of Lemaitre Vascular Inc. (LMAT), reported changes in his beneficial ownership of company securities.
- On December 6, 2025, Roberts acquired 3 shares of common stock upon the release of dividend equivalent rights.
- Concurrently, 99 shares and 10 shares of common stock were disposed of on December 6, 2025, at a price of $84.53 per share, to satisfy tax withholding obligations incurred upon the vesting of restricted stock units.
- Following these transactions, Roberts directly beneficially owns 21,812 shares of common stock.
- Roberts also acquired various dividend equivalent rights on December 4, 2025, totaling 20.2692 rights, and had 3 dividend equivalent rights released on December 6, 2025.
- The total number of dividend equivalent rights beneficially owned after these transactions is 187.2359.
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions primarily related to the vesting of equity awards and associated tax withholding, which is a neutral event.
Positives
- The vesting of restricted stock units and performance share units indicates the achievement of prior compensation milestones for the insider.
- Accrual of additional dividend equivalent rights, which are economic equivalents of common stock, increases potential future equity holdings for the insider.
Negatives
- A net reduction of 106 shares of common stock in direct beneficial ownership due to shares withheld for tax obligations, although this is a common practice for equity compensation.
Stakeholder Impact
- Shareholders: The transactions represent routine equity compensation activities for a key executive and do not indicate a significant change in company fundamentals or insider sentiment beyond standard compensation practices.
Key Dates
| Date | Description |
|---|---|
| 12/11/2021 | Restricted stock unit award granted, on which dividend equivalent rights accrued. |
| 12/12/2022 | Restricted stock unit and performance share unit awards granted, on which dividend equivalent rights accrued. |
| 12/08/2023 | Restricted stock unit and performance share unit awards granted, on which dividend equivalent rights accrued. |
| 12/06/2024 | Restricted stock unit award granted, on which dividend equivalent rights accrued; vesting of a restricted stock unit award leading to tax withholding. |
| 02/18/2025 | Restricted stock unit award granted, on which dividend equivalent rights accrued; vesting of a restricted stock unit award leading to tax withholding. |
| 12/04/2025 | Earliest transaction date reported; acquisition of various dividend equivalent rights. |
| 12/06/2025 | Common stock acquisition upon release of dividend equivalent rights; common stock dispositions for tax withholding; release of dividend equivalent rights. |
| 12/08/2025 | Signature date of the reporting person's attorney-in-fact. |
Recommendation
holdThe Form 4 details routine insider transactions related to equity compensation vesting and tax withholding. These are standard events and do not provide new information that would alter an investment thesis for Lemaitre Vascular.
Keywords
Lemaitre Vascular, LMAT, Form 4, Insider Trading, Beneficial Ownership, Stock Transactions, Restricted Stock Units, Dividend Equivalent Rights, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.